A Comparative Analysis of Models Used to Evaluate the Cost-Effectiveness of Dabigatran Versus Warfarin for the Prevention of Stroke in Atrial FibrillationSORENSEN, Sonja V; SIYANG PENG; MONZ, Brigitta U et al.PharmacoEconomics (Auckland). 2013, Vol 31, Num 7, pp 589-604, issn 1170-7690, 16 p.Article

Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada: Comparative efficacy and cost-effectivenessKANSAL, Anuraag R; SHARMA, Michael; BRADLEY-KENNEDY, Carole et al.Thrombosis and haemostasis. 2012, Vol 108, Num 4, pp 672-682, issn 0340-6245, 11 p.Article

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspectiveSORENSEN, Sonja V; KANSAL, Anuraag R; CONNOLLY, Stuart et al.Thrombosis and haemostasis. 2011, Vol 105, Num 5, pp 908-919, issn 0340-6245, 12 p.Article

Comparison of the Cost-effectiveness of New Oral Anticoagulants for the Prevention of Stroke and Systemic Embolism in Atrial Fibrillation in a UK SettingZHENG, Ying; SORENSEN, Sonja V; GONSCHIOR, Ann-Katrin et al.Clinical therapeutics. 2014, Vol 36, Num 12, pp 2015-2028, issn 0149-2918, 14 p.Article

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillationKANSAL, Anuraag R; SORENSEN, Sonja V; GANI, Ray et al.Heart (London 1996). 2012, Vol 98, Num 7, pp 573-578, issn 1355-6037, 6 p.Article